Assertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.18, $0.27 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $49.46 million versus the consensus estimate of $27.02 million.

GUIDANCE:

Assertio Therapeutics sees FY2025 revenue of $110-112 million, versus the consensus of $111.1 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.